The following articles (labelled with PubMed ID or TBD) are for your review
||Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC┐ inhibitors.
||Takeda Pharmaceutical Company, Ltd
||Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
||Icahn School of Medicine at Mount Sinai
||Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
||Universit£ degli Studi di Parma
||A quantitative analysis of kinase inhibitor selectivity.
||Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
||Harvard Medical School
||Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).
||Comprehensive analysis of kinase inhibitor selectivity.
||AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
||Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
||University of Zurich
||Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
||A small molecule-kinase interaction map for clinical kinase inhibitors.
||A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.
||Moffitt Cancer Center and Research Institute